HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Strikingly, two HDAC inhibitors, vorinostat (Merck) and romidepsin (Gloucester Pharmaceuticals), which reportedly showed inhibitory effects on melanoma growth, were approved by the US FDA for the treatment of cutaneous T-cell lymphoma[30-34].